[{"id":"bd316351-bd1c-4019-8db7-db0943251c71","acronym":"","url":"https://clinicaltrials.gov/study/NCT03364400","created_at":"2021-01-17T17:22:02.370Z","updated_at":"2024-07-02T16:35:48.034Z","phase":"Phase 1","brief_title":"Phase 1 Study Evaluating VT1021 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT03364400","lead_sponsor":"Vigeo Therapeutics, Inc.","biomarkers":" BRCA • CD36","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA • CD36"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VT1021"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 116","initiation":"Initiation: 11/28/2017","start_date":" 11/28/2017","primary_txt":" Primary completion: 01/01/2024","primary_completion_date":" 01/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2023-05-15"},{"id":"6d778386-93bc-43df-aca0-788f12fcfb93","acronym":"PROMISE","url":"https://clinicaltrials.gov/study/NCT02694809","created_at":"2021-01-18T13:09:19.110Z","updated_at":"2024-07-02T16:35:56.250Z","phase":"Phase 2","brief_title":"The PROMISE Study: Duavee in Women With DCIS","source_id_and_acronym":"NCT02694809 - PROMISE","lead_sponsor":"Northwestern University","biomarkers":" HER-2 • PGR • CD36 • PTGS2","pipe":" | ","alterations":" HER-2 expression • PGR expression","tags":["HER-2 • PGR • CD36 • PTGS2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • PGR expression"],"overall_status":"Recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 01/01/2017","start_date":" 01/01/2017","primary_txt":" Primary completion: 08/01/2023","primary_completion_date":" 08/01/2023","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2023-02-07"},{"id":"30aef5c9-4186-4030-80ca-8f512afdcdbc","acronym":"IOSCAR","url":"https://clinicaltrials.gov/study/NCT04624828","created_at":"2021-01-19T20:35:18.695Z","updated_at":"2024-07-02T16:35:56.368Z","phase":"","brief_title":"Immune Response Evaluation in Oligorecurrent and Oligoprogressive Prostate Cancer Patients Treated With SBRT","source_id_and_acronym":"NCT04624828 - IOSCAR","lead_sponsor":"Istituto Clinico Humanitas","biomarkers":" PD-1 • HAVCR2 • IL2RA • TIGIT • CD36 • CD24 • ENTPD1 • KLRG1 • CEACAM8 • ISG20","pipe":"","alterations":" ","tags":["PD-1 • HAVCR2 • IL2RA • TIGIT • CD36 • CD24 • ENTPD1 • KLRG1 • CEACAM8 • ISG20"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 10/19/2020","start_date":" 10/19/2020","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-02-06"},{"id":"2bf15b4f-9a49-45d6-8256-e8bb3a627793","acronym":"","url":"https://clinicaltrials.gov/study/NCT03598582","created_at":"2021-01-18T17:41:35.717Z","updated_at":"2024-07-02T16:37:08.648Z","phase":"Phase 4","brief_title":"Biological Predictive Factors of Response to ESA in Low Risk MDS Patients","source_id_and_acronym":"NCT03598582","lead_sponsor":"Association pour la recherche sur les Affections Malignes en Immunologie Sanguine","biomarkers":" CD34 • GDF15 • CD36 • TFRC","pipe":"","alterations":" ","tags":["CD34 • GDF15 • CD36 • TFRC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Retacrit (epoetin alfa-epbx)"],"overall_status":"Completed","enrollment":" Enrollment 70","initiation":"Initiation: 01/01/2013","start_date":" 01/01/2013","primary_txt":" Primary completion: 05/01/2017","primary_completion_date":" 05/01/2017","study_txt":" Completion: 05/01/2018","study_completion_date":" 05/01/2018","last_update_posted":"2018-07-26"}]